Hall Brett, Dembinski Jennifer, Sasser A Kate, Studeny Matus, Andreeff Michael, Marini Frank
Department of Pediatrics, The Ohio State University and Center for Childhood Cancer, Columbus Children's Research Institute, Columbus, OH, USA.
Int J Hematol. 2007 Jul;86(1):8-16. doi: 10.1532/IJH97.06230.
Recent evidence suggests that mesenchymal stem cells (MSC) selectively home to tumors, where they contribute to the formation of tumor-associated stroma. This effect can be opposed by genetically modifying MSC to produce high levels of anti-cancer agents that blunt tumor growth kinetics and inhibit the growth of tumors in situ. In this review article, we describe the biological properties of MSC within the tumor microenvironment and discuss the potential use of MSC and other bone marrow-derived cell populations as delivery vehicles for antitumor proteins.
近期证据表明，间充质干细胞（MSC）可选择性归巢至肿瘤部位，在那里它们有助于肿瘤相关基质的形成。通过基因改造MSC以产生高水平的抗癌药物，从而减弱肿瘤生长动力学并抑制原位肿瘤生长，可对抗这种效应。在这篇综述文章中，我们描述了肿瘤微环境中MSC的生物学特性，并讨论了MSC及其他骨髓来源细胞群体作为抗肿瘤蛋白递送载体的潜在用途。
